SAKK/Novartis Translational Prostate Cancer Research Award

We invite you to uncover new horizons in the fight against prostate cancer.

SAKK's Prostate Cancer Research Award is funded by Novartis and aims to support ongoing translational prostate cancer research. The grant is worth CHF 20 000. 

Eligible Projects

Projects should be translational in nature. That is, they should be aimed at translating basic research discoveries into the clinic. Possible projects could include, but are not limited to:

  • Development of novel treatments for prostate cancer focused on small molecules, biologics, or radioligand therapies
  • Development of diagnostic modalities for prostate cancer
  • Development of novel prevention strategies for prostate cancer


  • Approaches should include preclinical, animal, human tissue, and/or human studies
  • Basic research discovery projects are out of scope
  • Must be conducted in Switzerland, but can be part of larger collaborative projects. In case of the latter, the submitted project should be a substantial part of such an overarching project and focus on a specific aspect. Only costs that are still occurring can be covered by the award.
  • Be written in English language
  • The abstract of not more than 300 words should include a project title, the rationale, aim of the project, and how this research will be translated into the clinic.

Eligible Applicants

Applicants must have a primary place of work in Switzerland and can include graduate or postgraduate researchers or physician-scientists.

Applications that do not fulfill all of the above-mentioned requirements cannot be considered.

Submissions: Applications have to be submitted electronically via SAKK to

Application deadline: September 30, 2024

For further information please refer to the documents below.


In collaboration with           Novartis_Logo